Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Starting Big

This article was originally published in Start Up

Executive Summary

Increasing fund size, a depressed but competitive public stock market, and rule-bound money managers unable to even consider investing in small firms are compelling private investors to seek new, deliberately big models for start-up firms. Some VCs are making long-term bets on star-powered teams of people trying to integrate brand-new technologies. If fully-formed start-ups can dramatically improve the drug discovery process, and retain the value they build, they stand to enjoy huge step-ups in valuation when they eventually do go public. Investors seeking faster-than-average returns think they can quickly build integrated-technology companies by buying the basic underpinnings at discount-for instance, by acquiring experienced research groups from major drugmakers anxious to cut costs-then quickly taking the start-ups public. In-licensing may also offer a faster route to ROI. Investors are updating the old model, applying stacks of cash to help certain start-ups acquire operating infrastructure, and reach for big opportunities. Backers expect that big-name founders will be able to net products that elude less experienced people.
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090343

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel